Ephrin B expression in epithelial ovarian neoplasms correlates with tumor differentiation and angiogenesis - PubMed (original) (raw)
Ephrin B expression in epithelial ovarian neoplasms correlates with tumor differentiation and angiogenesis
Josep Castellvi et al. Hum Pathol. 2006 Jul.
Abstract
Differential gene expression studies are identifying new sets of genes with a role in the classification, differential diagnosis, and prognosis of some human tumors. Ephrin B1, a factor involved in angiogenesis, has been shown to be up-regulated in ovarian carcinomas, making it a potential target for cancer treatment. This study investigates ephrin B expression in ovarian tumors to validate results from gene expression studies and evaluates its significance with a clinical-pathological correlation. Specimens from 112 benign, borderline, and malignant epithelial ovarian tumors were examined. Tissue microarrays were constructed, and ephrin B expression was studied by immunohistochemistry. To correlate ephrin B expression with angiogenesis, CD31 immunostaining was performed to assess microvessel density. Ephrin B was detected in 50% of ovarian tumors: clear cell carcinomas (93%), serous carcinomas (74%), mucinous carcinomas (29%), and endometrioid carcinomas (27%). High-grade carcinomas showed greatest ephrin B expression, whereas benign tumors and low-grade carcinomas were rarely positive. A correlation was found between ephrin B expression and microvessel density, supporting the angiogenic role of this factor in ovarian carcinomas. Ephrin B expression was associated with higher rates of disease recurrence and a decrease in overall survival. A distinctive pattern of ephrin B expression was observed in ovarian tumors: high-grade tumors and clear cell and serous carcinomas show higher expression, correlating with the aggressiveness. On the other hand, ephrin B expression correlated with microvessel density of the tumors. Because Eph receptors and ephrins are targets for new therapeutic inhibitors, this pattern of ephrin B expression should be considered in future clinical studies.
Similar articles
- Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer.
Castellvi J, Garcia A, Rojo F, Ruiz-Marcellan C, Gil A, Baselga J, Ramon y Cajal S. Castellvi J, et al. Cancer. 2006 Oct 15;107(8):1801-11. doi: 10.1002/cncr.22195. Cancer. 2006. PMID: 16983702 - Cathepsin D in ovarian cancer: prognostic value and correlation with p53 expression and microvessel density.
Lösch A, Schindl M, Kohlberger P, Lahodny J, Breitenecker G, Horvat R, Birner P. Lösch A, et al. Gynecol Oncol. 2004 Feb;92(2):545-52. doi: 10.1016/j.ygyno.2003.11.016. Gynecol Oncol. 2004. PMID: 14766246 - [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL, Shen DH, Xue WC, Li Y, Yu YZ. Shao HL, et al. Zhonghua Fu Chan Ke Za Zhi. 2007 Apr;42(4):227-32. Zhonghua Fu Chan Ke Za Zhi. 2007. PMID: 17631760 Chinese. - Regulation of angiogenesis by Eph-ephrin interactions.
Kuijper S, Turner CJ, Adams RH. Kuijper S, et al. Trends Cardiovasc Med. 2007 Jul;17(5):145-51. doi: 10.1016/j.tcm.2007.03.003. Trends Cardiovasc Med. 2007. PMID: 17574121 Review. - Ovarian epithelial tumors of low malignant potential: are they precursors of ovarian carcinoma?
Fukumoto M, Nakayama K. Fukumoto M, et al. Pathol Int. 2006 May;56(5):233-9. doi: 10.1111/j.1440-1827.2006.01960.x. Pathol Int. 2006. PMID: 16669871 Review.
Cited by
- Tyrosine Phosphorylation Profiling Revealed the Signaling Network Characteristics of CAMKK2 in Gastric Adenocarcinoma.
Najar MA, Arefian M, Sidransky D, Gowda H, Prasad TSK, Modi PK, Chatterjee A. Najar MA, et al. Front Genet. 2022 May 13;13:854764. doi: 10.3389/fgene.2022.854764. eCollection 2022. Front Genet. 2022. PMID: 35646067 Free PMC article. - The EPH/Ephrin System in Gynecological Cancers: Focusing on the Roots of Carcinogenesis for Better Patient Management.
Psilopatis I, Pergaris A, Vrettou K, Tsourouflis G, Theocharis S. Psilopatis I, et al. Int J Mol Sci. 2022 Mar 17;23(6):3249. doi: 10.3390/ijms23063249. Int J Mol Sci. 2022. PMID: 35328669 Free PMC article. Review. - The Clinical Impact of the EPH/Ephrin System in Cancer: Unwinding the Thread.
Pergaris A, Danas E, Goutas D, Sykaras AG, Soranidis A, Theocharis S. Pergaris A, et al. Int J Mol Sci. 2021 Aug 5;22(16):8412. doi: 10.3390/ijms22168412. Int J Mol Sci. 2021. PMID: 34445116 Free PMC article. Review. - Ephrin-B1 Is a Novel Biomarker of Bladder Cancer Aggressiveness. Studies in Murine Models and in Human Samples.
Mencucci MV, Lapyckyj L, Rosso M, Besso MJ, Belgorosky D, Isola M, Vanzulli S, Lodillinsky C, Eiján AM, Tejerizo JC, Gonzalez MI, Zubieta ME, Vazquez-Levin MH. Mencucci MV, et al. Front Oncol. 2020 Mar 27;10:283. doi: 10.3389/fonc.2020.00283. eCollection 2020. Front Oncol. 2020. PMID: 32292715 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous